The Health 202: One GOP senator is urging the drug industry to make good on lowering prices

Washington Post, March 6, 2019
Paulina Firozi, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "Mitchell said the bill still highlights the 'bipartisan energy' around addressing skyrocketing drug costs. And Rachel Sachs, an associate professor of law at Washington University…

Read More

Treat Medicines Like Netflix Treats Shows

New York Times, March 5, 2019
Tina Rosenberg, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "The Netflix business model makes particular sense for hep C drugs, said Rachel Sachs, an associate professor of law at Washington University School of Law. Hep C is a communicable disease, so governments have a strong public health…

Read More

Rebate Ban Became Trump’s Way to Cut Drug Costs Without Congress

Bloomberg Law, March 4, 2019
Madison Alder, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "Eliminating certain drug rebates in federal health insurance programs is the one tool the Trump administration has to produce the biggest impact on pricing without the help of Congress, though even it isn’t sure how much this…

Read More

Drug Companies and Doctors Battle Over the Future of Fecal Transplants

New York Times, March 3, 2019
Andrew Jacobs, citing research by Rachel Sachs (Academic Fellow Alumna)

From the article: "CAMBRIDGE, Mass. — There’s a new war raging in health care, with hundreds of millions of dollars at stake and thousands of lives in the balance. The battle, pitting drug companies against doctors and patient advocates,…

Read More

Drugs could get more expensive for American patients because Big Pharma is spending MAJOR…

Daily Mail, March 1, 2019
Valerie Bauman, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "In the first two months of 2019, the pharmaceutical companies have already struck $146 billion-worth of deals to takeover promising new biotechs, according to a report by Dealogic, a business intelligence firm.

Read More

Pharma’s day in Congress: 'A hearing not a show'

BioPharma Dive, February 26, 2019
Ned Pagliarulo and Andrew Dunn, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "Criticism from several Republican senators was notable, namely in how similar the conservatives sounded to their Democratic counterparts. Lawmakers on both sides of the aisle were "advancing very…

Read More

Pharma executives in the hot seat over drug prices

Marketplace, February 26, 2019
Erika Beras, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "Drug prices are also increasing at nearly ten times the rate of inflation, according to a report by another Senate committee. One of the first questions lawmakers are likely to ask the executives is: why?

Read More

In Florida, Drug Importation From Canada Finds New Champions, Old Snags

Kaiser Health News, February 25, 2019
by Shefali Luthra and Phil Galewitz, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "And how much would these programs help anyway? While statehouses may be abuzz, in Washington, national politics impedes feasibility. And skeptics question how much relief these initiatives could actually provide.

Read More

Payments for Research Can Lead to Lies: Study

US News and World Report, February 21, 2019
by Robert Preidt, quoting Emily Largent (Student Fellow Alumna)

From the article: "Payment is often used to get people to enroll in studies, but there has been little research on whether and to what extent people will lie about their eligibility or other aspects of participation to get paid.

Read More

DeSantis wants access to Canadian prescription drugs to drop Florida’s healthcare cost

Miami Herald, February 20, 2019
by Emily L. Mahoney and Elizabeth Koh, quoting Rachel Sachs

From the article: "Supporters of such proposals say it could save millions in rising prescription drug costs in the United States, and DeSantis suggested similar savings could come to Florida. But others have raised concerns about how to ensure the…

Read More

What’s the future of human gene editing?: Balancing ethical and religious concerns with evidence-based uses of genetic technologies

Genetic Literacy Project, February 19, 2019
by Naomi Scheinerman, quoting I. Glenn Cohen (Faculty Director)

From the article: "In the legislative realm, the US Congress is poised to renew its ban on creating CRISPR babies, as well as “three-parent babies” that are used to prevent mitochondrial disease inheritance. But blocking all…

Read More

Drug costs a top issue in 2020 elections

Columbus Dispatch, February 17, 2019
by Jessica Wehrman, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "Rachel Sachs, an associate law professor at Washington University in St. Louis, said there has been a spate of proposals in recent years to allow the government to negotiate with drug companies for Medicare Part D, but they haven’t…

Read More

A Mother Learns the Identity of Her Child’s Grandmother. A Sperm Bank Threatens to Sue.

New York Times, February 16, 2019
by Jacqueline Mroz, quoting I. Glenn Cohen (Faculty Director)

From the article: "I. Glenn Cohen, a professor and bioethicist at Harvard Law School, agreed and questioned whether such a contract is “contrary to public policy” and thus unenforceable. The mother of…

Read More

House committee weighs drug pricing proposals

Endpoints News, February 14, 2019
by Michael Mezher, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "Mark Miller, executive vice president of health care at Arnold Ventures, told the committee that moving to a flat fee-per-prescription model for Medicare Part B could help to curb some spending. Both…

Read More

Can California Beat The Federal Government In Lowering Drug Prices?

Kaiser Health News, February 14, 2019
By Samantha Young, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "Lawmakers face an array of challenges that make reform hard, such as secretive drug pricing and the political influence of the pharmaceutical industry, one of the most powerful lobbies in the country, said Rachel Sachs, an associate…

Read More

Sanders to Gables pharma firm: Why are you charging $375,000 for life-saving drug?

Miami Herald, February 6, 2019
by Rob Wile, quoting W. Nicholson Price (Academic Fellow Alumnus)

From the article: "Nicholson Price, an assistant professor at the University of Michigan who specializes in law surrounding innovation in the life sciences, said Catalyst would likely counter by saying it was responsible for spending the money to…

Read More

Biotech’s Boom Year

Chemistry World, February 13, 2019
by Anthony King, quoting Jonathan J. Darrow (Student Fellow Alumnus)

From the article: "Another factor pushing venture capital investments, and perhaps IPO enthusiasm, are the premium prices paid by big companies when acquiring smaller firms. ‘Some of the increases in valuations could be driven by the willingness…

Read More

Can You Sue An Algorithm For Malpractice?

Forbes AI, February 11, 2019
by Forbes AI, interviewing W. Nicholson Price (Academic Fellow Alumnus)

From the article: "What’s in the box? The “black box,” that is. Increasingly, doctors are relying on sophisticated, and at times inscrutable, algorithms to make healthcare recommendations—a practice dubbed “black…

Read More

How Trump’s Latest Plan to Cut Drug Prices Will Affect You

New York Times, February 5, 2019
By Katie Thomas and Reed Abelson, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "The Trump administration says that a lot will depend on how companies react. If the plan takes effect next year, it could cost the government an extra $2.8 billion to $13.5 billion that same year. But…

Read More

Trump wants to slash drug rebate deals. Will it make a difference?

ABC News, February 4, 2019
by Jay Hancock, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "In any event, it’s hardly a pure win for seniors or patients in general. Consumers are unlikely to collect the full benefit of eliminated rebates. At the same time, the change would produce…

Read More